IMMUNOLOGY2026™ Conference Recordings For Attendees-Itaconate alleviates autoimmune uveitis by boosting FOXP3 and blocking succinate-driven inflammation

Itaconate alleviates autoimmune uveitis by boosting FOXP3 and blocking succinate-driven inflammation

Video Transcription

Video Summary

Sukhwinder Singh presented research on metabolic regulation in ocular autoimmunity, focusing on autoimmune uveitis. The study examined the host metabolite itaconate, produced by IRG1, and its role in controlling inflammation in the eye. Using IRG1 knockout mice, the team found worsened retinal lesions, disrupted retinal structure, reduced visual function, increased macrophages and IL-17A-producing CD4 T cells, lowered regulatory T cells, and elevated inflammatory cytokines. In contrast, treatment with 4-octyl itaconate reduced retinal damage, preserved ERG function, decreased inflammatory cytokines, suppressed glycolysis in stimulated immune cells, and increased FOXP3 regulatory T cells along with IL-10 and TGF-beta. The work also showed that itaconate countered succinate-driven inflammation. Overall, the findings suggest itaconate has therapeutic potential in autoimmune uveitis by promoting immune regulation and limiting inflammatory pathways.

Meta Tag

Date April 16, 2026 4:15 PM - 4:30 PM

Room 253

Session Immunometabolism in Autoimmunity

Speaker Sukhvinder Singh

Track Basic Autoimmunity (BA)

Year 2026

Keywords

autoimmune uveitis

itaconate

IRG1 knockout

retinal inflammation

regulatory T cells

April 16, 2026 4:15 PM - 4:30 PM

253

Immunometabolism in Autoimmunity

Sukhvinder Singh

Basic Autoimmunity (BA)

2026